Read our latest white paper on the significant economic and clinical burden of Respiratory Syncytial Virus (#RSV) in older adults in select high-income APEC countries. Download the full whitepaper here: https://lnkd.in/g_UJDXf7
What is the true cost of Respiratory Syncytial Virus (#RSV) in older adults across APEC? In our latest white paper, we delve into the significant economic and clinical burden of RSV in older adults in select high-income APEC countries. Our study found that an average of 1 in 500 older adults were hospitalized annually with RSV, leading to an estimated 778,000 hospitalizations and USD 2.8 billion in costs in 2023. The highest burden was observed in China, followed by Japan and Canada. Read the full report to gain deeper insights into the impact of RSV on health systems and the urgent need for strategic interventions to alleviate this significant health and economic burden. Download the full white paper here: https://bit.ly/4faZusM Funding for this work was provided by GSK. Authors: Annoda Kumar – Saurabh Trikha, PhD – Dr. Mansi Mehta – Smitha Sreedharan – Mou Chatterjee #publichealth #whitepaper